par Rossi, J-F;van Hoof, Achiel;de Boeck, K;Johnson, S A;Bron, Dominique
;Foussard, C;Lister, T A;Berthou, C;Kramer, M.;Littlewood, T J;Marcus, R E;Deconinck, E;Montillo, M;Guibon, O;Tollerfield, S M
Référence Journal of clinical oncology, 22, 7, page (1260-1267)
Publication Publié, 2004-04

Référence Journal of clinical oncology, 22, 7, page (1260-1267)
Publication Publié, 2004-04
Article révisé par les pairs
Titre: |
|
Auteur: | Rossi, J-F; van Hoof, Achiel; de Boeck, K; Johnson, S A; Bron, Dominique; Foussard, C; Lister, T A; Berthou, C; Kramer, M.; Littlewood, T J; Marcus, R E; Deconinck, E; Montillo, M; Guibon, O; Tollerfield, S M |
Informations sur la publication: | Journal of clinical oncology, 22, 7, page (1260-1267) |
Statut de publication: | Publié, 2004-04 |
Sujet CREF: | Sciences bio-médicales et agricoles |
MeSH keywords: | Administration, Oral |
Adult | |
Aged | |
Antimetabolites, Antineoplastic -- therapeutic use | |
Female | |
Humans | |
Leukemia, Lymphocytic, Chronic, B-Cell -- drug therapy | |
Male | |
Middle Aged | |
Prospective Studies | |
Quality of Life | |
Remission Induction | |
Retrospective Studies | |
Safety | |
Survival Rate | |
Treatment Outcome | |
Vidarabine Phosphate -- analogs & derivatives | |
Vidarabine Phosphate -- therapeutic use | |
Note générale: | Clinical Trial |
Clinical Trial, Phase II | |
Comparative Study | |
Journal Article | |
Multicenter Study | |
Research Support, Non-U.S. Gov't | |
Langue: | Anglais |
Identificateurs: | urn:issn:0732-183X |
info:doi/10.1200/JCO.2004.05.012 | |
info:pii/JCO.2004.05.012 | |
info:pmid/15051774 |